Tislelizumab for solid tumors with a high immune gene score
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a single immunotherapy drug (tislelizumab) for people with advanced solid tumors that haven't responded to other treatments. It's for those who haven't had immunotherapy before and have a specific genetic marker in their tumor that suggests their immune system might be more active.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years old or older.
- You have a solid tumor that has spread (advanced or metastatic) and standard treatments are not helping or available.
- You have a special genetic test result showing a 'T cell inflamed' score of 0.857 or higher, measured from a tumor sample taken within the last 2 years.
- You are able to do daily activities on your own (ECOG score 0 or 1).
- Your blood counts, kidney, and liver function are within certain limits (your doctor will check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies tislelizumab, an immune treatment that blocks PD-1, in people with MSI-H or dMMR solid tumors that cannot be fully removed or have spread, after other treatment has already been tried. It may help your immune system recognize and fight the cancer.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.
This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.
This study tests a new treatment using your body's own immune cells (called tumor-infiltrating lymphocytes) that are taken from your tumor, grown in a lab, and then put back into you. It's for people with advanced solid tumors who have run out of standard options.
Hear when a new Refractory Solid Cancer Patients Unexposed to Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.